See the DrugPatentWatch profile for Qulipta
Qulipta, manufactured by AbbVie, is a prescription medication used for the preventive treatment of migraine [1]. As a relatively new drug, it is not yet available in generic form, and therefore, the cost is associated with the brand-name drug [1].
How much does Qulipta cost without insurance?
The list price for Qulipta can vary, but a 30-day supply typically costs several hundred dollars. For instance, a 30-count bottle of 60 mg tablets may be priced around $800 [2]. These costs can be substantial for individuals paying out-of-pocket.
What are the options for saving money on Qulipta?
For patients with commercial insurance, savings cards may be available through the manufacturer to reduce out-of-pocket expenses. Patients may be eligible for a co-pay as low as $10 for a 30-day supply, with a maximum savings of $300 per fill and an annual maximum of $3,600 [3]. Patients should check the manufacturer's website or their insurance provider for specific program details and eligibility requirements. For those without insurance, the cost remains at the full list price, though patient assistance programs might offer some relief if criteria are met.
When might a generic version of Qulipta become available?
The availability of a generic version of Qulipta depends on patent expirations and any potential patent challenges [4]. Drug patent information, including expiration dates and any related legal proceedings, can be tracked through resources like DrugPatentWatch.com [4]. Generally, it takes many years from a drug's approval for generic versions to enter the market, following the expiration of all relevant patents and regulatory approvals for the generic formulation.
What is the chemical makeup of Qulipta?
Qulipta's active ingredient is atogepant [1]. It belongs to a class of drugs called calcitonin gene-related peptide (CGRP) receptor antagonists [1]. This mechanism of action targets the pathways involved in migraine headaches.